Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sarepta Therapeutics Inc (NASDAQ:SRPT)

40.58
Delayed Data
As of 4:00pm ET
 -1.86 / -4.38%
Today’s Change
23.51
Today|||52-Week Range
63.73
+47.94%
Year-to-Date
Sarepta Therapeutics (SRPT) Stock Surged 24% Today: Here's Why
Jul 20 / Zacks.com - Paid Partner Content
Sarepta & BioMarin Settle Patent Litigation on Exon Skipping
Jul 19 / Zacks.com - Paid Partner Content
Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View
Jul 20 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs
Jul 19 / Zacks.com - Paid Partner Content
Biotech Movers: Sarepta, Inovio, Mylan
Jul 20 / TheStreet.com - Paid Partner Content
Mallinckrodt's MNK-1411 Gets Orphan Drug Status for DMD
Jul 13 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close42.44
Today’s open42.51
Day’s range40.12 - 42.77
Volume4,134,597
Average volume (3 months)2,209,039
Market cap$2.7B
Dividend yield--
Data as of 4:00pm ET, 07/27/2017

Growth & Valuation

Earnings growth (last year)-5.58%
Earnings growth (this year)+79.53%
Earnings growth (next 5 years)+0.37%
Revenue growth (last year)+332.64%
P/E ratioNM
Price/Sales246.40
Price/Book6.90

Competitors

 Today’s
change
Today’s
% change
LGNDLigand Pharmaceutica...-1.89-1.53%
CBPOChina Biologic Produ...-0.25-0.25%
MDCOMedicines Co-0.38-0.99%
IRWDIronwood Pharmaceuti...-0.45-2.63%
Data as of 4:00pm ET, 07/27/2017

Financials

Last reporting dateJuly 19, 2017
EPS forecast (this quarter)-$0.87
Annual revenue (last year)$5.4M
Annual profit (last year)-$267.3M
Net profit margin-4,930.18%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Douglas S. Ingram
Executive VP, Chief Financial &
Business Officer
Sandesh Mahatme
Corporate headquarters
Cambridge, Massachusetts

Forecasts